Eli Lilly: the trials and tribulations of antibody patents
Working in the biomedicine department at Eli Lilly, Duane Marks says his work entails “pretty much all aspects touching on IP relating to our biomedicines”. Through the course of his career Marks, who is patent counsel in bioproducts, has practised in numerous areas including diagnostics, research tools, and medical devices.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
7 May 2026 A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.
5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.